We have located links that may give you full text access.
Journal Article
Review
Effects of incretin-based therapies on renal function.
European Journal of Pharmacology 2018 January 6
Glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors (collectively termed incretin-based therapies) represent two of the most widely used classes of antidiabetic drugs. These compounds exert their beneficial effects on carbohydrate metabolism through the activation of specific glucagon like peptide-1 receptors in various organs. Accumulating evidence suggests that glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors also affect renal function in both glucagon like peptide-1 receptor-dependent and independent manner. However, the clinical significance of these observations remains indeterminate. In this review, we summarize the available preclinical and clinical data on the effects of incretin-based therapies on renal function indices and discuss their relevance in everyday clinical practise.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app